7α-(11-hydroxyundecyl)estra-1,3,5(10)-triene-3,17β-diol | 55592-09-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 7α-(11-hydroxyundecyl)estra-1,3,5(10)-triene-3,17β-diol
• 英文别名: 7α-(11'-hydroxy-undecyl) estra-1,3,5(10)-trien-3,17β-diol；(7R,8R,9S,13S,14S,17S)-7-(11-hydroxyundecyl)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
• CAS: 55592-09-1
• 化学式: C₂₉H₄₆O₃
• 分子量: 442.682
• InChiKey: JGEUAWIQQPNGCZ-LIHJZYAESA-N

物化性质

• 熔点：
  75-76 °C(Solv: ethyl ether (60-29-7))
• 沸点：
  600.1±55.0 °C(Predicted)
• 密度：
  1.063±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  8.1
• 重原子数：
  32
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7α-(11-hydroxyundecyl)estra-1,3,5(10)-triene-3,17β-diol 在 四溴化碳 、 碳酸氢钠 、 三苯基膦 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 16.0h， 生成 7α-(11-phenoxyundecyl)estra-1,3,5(10)-triene-3,17β-diol
  参考文献：
  名称：

  Synthesis and structure-affinity of a series of 7.alpha.-undecylestradiol derivatives: a potential vector for therapy and imaging of estrogen-receptor-positive cancers

  摘要：

  A series of 7 alpha-undecylestradiol derivatives, featuring various substituents at the end of the undecyl spacer chain, were synthesized and evaluated for their interaction with the estrogen receptor and nonreceptor sites. Their relative binding affinities (RBA) for calf uterine estrogen receptors were measured by competitive binding assays and varied between 0.5 and 8.4% of that of unlabeled 17 beta-estradiol. Enhanced lipophilicity and steric hindrance of the substituent on the end of the spacer chain resulted in decreased binding affinity for the estrogen receptor, while interactions with nonreceptor sites increased. RBA values were not affected by prolonged incubation times, suggesting a stable ligand-receptor complex. The potential to use the 7 alpha-undecylestradiol as a vector for site-selective delivery of diagnostic and therapeutic moieties to estrogen-receptor-positive human cancers is discussed.

  DOI：

  10.1021/jm00163a066
• 作为产物：
  描述：

  诺龙 以8%的产率得到
  参考文献：
  名称：

  DASILVA, JEAN N.;VAN, LIER JOHAN E., J. MED. CHEM., 33,(1990) N, C. 430-434

  摘要：

  DOI：

文献信息

• [EN] METHOD OF TREATMENT OF ANDROGEN-RELATED DISEASES
  申请人：ENDORECHERCHE INC.

  公开号：WO1991000733A1

  公开（公告）日：1991-01-24

  (EN) A method of treatment of androgen-related diseases such as prostate cancer in susceptible male animals, including humans, comprises administering novel antiandrogens and/or novel sex steroid biosynthesis inhibitors as part of a combination therapy. Sex steroid biosynthesis inhibitors, especially those capable of inhibiting conversion of dehydroepiandrosterone (DHEA) or 4-androstenedione ($g(D)4-dione) to natural sex steroida (and testosterone into dihydrotestosterone) in peripheral tissues, are used in combination with antiandrogens usually after blockade of testicular hormonal secretions. Antiestrogens can also be part of the combination therapy. Pharmaceutical compositions and two, three, four and five component kits are useful for such combination treatment.(FR) Le procédé décrit, qui sert à traiter les maladies associées aux androgènes, tels que les cancers de la prostate, chez des animaux mâles susceptibles de développer de telles pathologies, y compris chez l'homme, consiste à procéder à l'administration de nouveaux anti-androgènes et/ou de nouveaux inhibiteurs de biosynthèse des stéroïdes sexuels, cette administration faisant partie d'une thérapie combinée. Les inhibiteurs de biosynthèse des stéroïdes sexuels, tels qu'en particulier ceux qui sont capables d'inhiber la conversion de déhydroépiandrostéronea (DHEA) ou de 4-androsténedione ($g(D)4-dione) en stéroïdes sexuels naturels (et de testostérone en dihydrotestostérone) dans les tissus périphériques, sont utilisés en combinaison avec des anti-androgènes, habituellement après blocage des sécrétions hormonales testiculaires. L'administration d'anti-÷strogènes peut également faire partie de la thérapie combinée. Des compositions pharmaceutiques et deux, trois, quatre et cinq kits d'éléments utiles dans un tel traitement combiné sont décrits.

  一种治疗雄激素相关疾病的方法，例如易感雄性动物（包括人类）的前列腺癌，包括在组合疗法中给予新型抗雄激素和/或新型性激素合成抑制剂。性激素合成抑制剂，特别是那些能够抑制外周组织中脱氢表雄酮（DHEA）或4-雄烯二酮（$g（D）4-二酮）转化为天然性激素（和睾酮转化为双氢睾酮）的药物，通常在阻断睾丸激素分泌后与抗雄激素联合使用。抗雌激素也可以成为组合疗法的一部分。制药组合物和两个、三个、四个和五个成分的套装对于这种组合治疗非常有用。
• [EN] COMBINATION THERAPY FOR PROPHYLAXIS AND/OR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
  申请人：ENDORECHERCHE INC.

  公开号：WO1991000731A1

  公开（公告）日：1991-01-24

  (EN) A combination therapy for the prophylaxis and/or treatment of benign prostatic hyperplasia in susceptible warm-blooded animals which comprises administering a combination of two or more compounds selected from the group consisting of an inhibitor of 5$g(a)-reductase activity, an anti-estrogen, an inhibitor of aromatase activity, an inhibitor of 17$g(b)-hydroxysteroid dehydrogenase activity and, in some cases, an anti-androgen and/or an LHRH agonist. Pharmaceutical compositions useful for such treatment and pharmaceutical kits containing such compositions are disclosed.(FR) L'invention se rapporte à une thérapie combinée pour la prophylaxie et/ou le traitement de l'hyperplasie prostatique bénigne chez des animaux à sang chaud susceptibles de développer une telle pathologie. Cette thérapie consiste à administrer une combinaison d'au moins deux composés choisis dans le groupe constitué par un inhibiteur d'activité de 5$g(a)-réductase, par un anti-÷strogène, par un inhibiteur d'activité d'aromatase, par un inhibiteur d'activité de 17$g(b)-hydroxystéroïde déshydrogénase et, dans certains cas, par un anti-androgène et/ou par un agoniste de LHRH. Des compositions pharmaceutiques utilisées dans un tel traitement et des kits pharmaceutiques contenant de telles compositions sont décrits.

  一种用于易感温血动物预防和/或治疗良性前列腺增生的联合疗法，包括给予来自以下组合的两种或两种以上化合物的组合：5$g(a)-还原酶活性抑制剂、抗雌激素、芳香化酶活性抑制剂、17$g(b)-羟基类固醇脱氢酶活性抑制剂，以及在某些情况下，抗雄激素和/或LHRH激动剂。公开了用于此类治疗的制药组合物和包含这种组合物的制药工具包。
• Estrogen nucleus derivatives for use in the inhibition of sex steroid activity
  申请人：ENDORECHERCHE INC.

  公开号：EP0367576A2

  公开（公告）日：1990-05-09

  Novel derivatives of estrogenic nuclei, contain a side-chain substitution of the formula -R1[B-R2-]x L-G and may be used in pharmaceutical compositions as sex steroid activity inhibitors useful in the treatment of both androgen-related and estrogen-related diseases.

  雌激素核的新型衍生物，含有式-R1[B-R2-]x L-G的侧链取代物，可作为性类固醇活性抑制剂用于药物组合物中，可用于治疗与雄激素相关和与雌激素相关的疾病。
• Combinations for prophylaxsis and/or treatment of benign prostatic hyperplasia containing a 17 beta-hydroxy steroid dehydrogenase (17bHSD) inhibitor and at least one further active ingredient
  申请人：ENDORECHERCHE INC.

  公开号：EP0857487A2

  公开（公告）日：1998-08-12

  A therapeutic combination, useful in the treatment of benign prostatic hyperplasia, includes an inhibitor of 17β-hydroxysteroid dehydrogenase activity and at least one further active ingredient selected from the group comprising antiestrogens, inhibitors of 5α-reductase activity and inhibitors of aromatase activity. Pharmaceutical compositions and kits useful for such treatment are also provided.

  一种可用于治疗良性前列腺增生症的治疗组合物包括一种 17β-羟基类固醇脱氢酶活性抑制剂和至少一种选自抗雌激素、5α-还原酶活性抑制剂和芳香化酶活性抑制剂的其他活性成分。此外，还提供了用于此类治疗的药物组合物和试剂盒。
• Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
  申请人：ENDORECHERCHE INC.

  公开号：EP0943328A2

  公开（公告）日：1999-09-22

  A therapeutic combination, useful in the treatment or prevention of benign prostatic hyperplasia, includes an antiestrogen and at least one further active ingredient selected from the group consisting of inhibitors of aromatase activity and inhibitors of 5α-reductase activity. Pharmaceutical compositions and kits useful for such treatment are also provided.

  一种可用于治疗或预防良性前列腺增生症的治疗组合物包括一种抗雌激素和至少一种选自芳香化酶活性抑制剂和 5α 还原酶活性抑制剂的活性成分。 还提供了用于此类治疗的药物组合物和试剂盒。